Learn Peptide
Peptide Directory

Category · 20 peptides

Weight Loss & Metabolic

GLP-1 and metabolic peptides studied for fat loss, appetite regulation, and glucose control.

5-Amino-1MQPreclinical
An orally active small-molecule NNMT inhibitor with reproducible fat-loss and muscle data in mice but zero published human trials.
  • Fat mass reduction
  • Increased metabolic rate / thermogenesis
  • NAD+ pool preservation
7 studiesdosing4 stacks
AdipotidePreclinical
A synthetic peptidomimetic that starves white fat tissue by triggering apoptosis in the blood vessels that feed it.
  • Substantial fat-mass reduction
  • Vascular-targeted rather than appetite-based
  • Proof-of-mechanism in humans
3 studies
AICARPreclinical
A non-peptide AMPK-activating nucleotide analog studied as an "exercise mimetic" for endurance, fat oxidation, and metabolic regulation.
  • Endurance / exercise mimicry
  • Fat oxidation
  • Glucose regulation
8 studies
AOD-9604Emerging
A tyrosine-modified fragment of growth hormone engineered to isolate GH's fat-burning action from its growth effects, that cleanly delivered selective lipolysis in trials but failed to produce meaningful weight loss in humans.
  • Selective lipolysis without IGF-1 elevation
  • Fat mobilization in preclinical models
  • No glucose or insulin disruption
3 studiesdosing4 stacks
CagrilintideModerate
A long-acting amylin analogue that reinforces satiety through a pathway distinct from GLP-1, best known as the amylin half of the CagriSema combination.
  • Weight loss
  • Appetite suppression via a non-GLP-1 pathway
  • Mechanistic synergy with semaglutide (CagriSema)
10 studiesdosing3 stacks
CagriSemaEstablished
The first fixed-dose GLP-1 plus amylin combination, pairing semaglutide and cagrilintide in a single once-weekly injection for deep weight loss.
  • Deep weight loss
  • Superior to either agent alone
  • High responder rates
3 studiesdosing1 stacks
ExenatideEmerging
A GLP-1 receptor agonist researched for its effects on metabolism and appetite regulation.
  • Appetite regulation
  • Metabolic effect
GLP-1 (7-37)Emerging
The native, full-length active form of glucagon-like peptide-1 — the endogenous incretin hormone that the entire GLP-1 receptor agonist drug class is modeled on.
  • Glucose-dependent insulin secretion
  • Blood glucose regulation
  • Glucagon suppression
2 studiesdosing
HGH Fragment 176-191Preclinical
The C-terminal fat-burning fragment of growth hormone, designed to isolate lipolysis without the IGF-1 and growth effects of full GH — but whose clinical-development cousin AOD-9604 failed its pivotal obesity trial.
  • Targeted lipolysis (fat mobilization)
  • Inhibition of lipogenesis
  • Fat loss without IGF-1 elevation
4 studiesdosing4 stacks
LiraglutideFDA-Approved
The first long-acting GLP-1 receptor agonist approved for obesity, a once-daily injection that reduces appetite and blood sugar.
  • Meaningful weight loss
  • Appetite suppression and satiety
  • Blood sugar regulation
12 studiesdosing
MazdutideEstablished
A once-weekly dual GLP-1/glucagon receptor agonist that became the first dual incretin approved for obesity, reaching market in China in 2025.
  • Substantial weight loss
  • Increased resting energy expenditure
  • Improved hepatic (NAFLD/MASH) markers
4 studiesdosing3 stacks
OrforglipronFDA-Approved
The first non-peptide, small-molecule oral GLP-1 receptor agonist — a once-daily weight-management pill, no injection required.
  • Clinically meaningful weight loss
  • Glycemic control in type 2 diabetes
  • Oral convenience with no food-timing restrictions
7 studiesdosing4 stacks
OxyntomodulinModerate
An endogenous gut hormone that acts as a dual GLP-1/glucagon receptor agonist, suppressing appetite while raising energy expenditure.
  • Appetite suppression
  • Increased energy expenditure
  • Fat oxidation
5 studiesdosing
PramlintideFDA-Approved
An FDA-approved synthetic amylin analogue that slows gastric emptying, suppresses glucagon, and enhances meal-related satiety.
  • Appetite suppression and satiety
  • Weight loss
  • Postprandial glucose control
4 studiesdosing2 stacks
RetatrutideEmerging
An investigational once-weekly triple GLP-1/GIP/glucagon receptor agonist that has produced the deepest weight-loss numbers ever recorded in obesity trials.
  • Record-setting weight loss
  • Powerful appetite suppression
  • Increased energy expenditure
10 studiesdosing4 stacks
SemaglutideFDA-Approved
The FDA-approved GLP-1 receptor agonist that turned obesity into a pharmacology problem, delivering ~15% body weight loss with once-weekly dosing.
  • Substantial, sustained weight loss
  • Appetite and 'food noise' suppression
  • Cardiovascular event reduction
8 studiesdosing2 stacks
SLU-PP-332Preclinical
A small-molecule pan-ERR agonist marketed as 'exercise in a pill' with reproducible endurance and fat-oxidation data in mice and zero human evidence.
  • Exercise-mimetic gene program
  • Increased endurance capacity
  • Enhanced fat oxidation
4 studiesdosing2 stacks
SLU-PP-915Preclinical
The orally active successor to SLU-PP-332: the same pan-ERR exercise-mimetic mechanism, chemically re-engineered to survive the gut, but still mouse-only.
  • Oral bioavailability
  • Increased exercise capacity
  • Exercise-mimetic gene signature in muscle
2 studies
SurvodutideModerate
An investigational once-weekly dual GLP-1/glucagon receptor agonist delivering strong weight loss plus a standout liver-fat (MASH) effect.
  • Substantial weight loss
  • MASH / liver-fat improvement
  • Glucagon-driven energy expenditure
3 studiesdosing
TirzepatideFDA-Approved
A once-weekly dual GIP/GLP-1 receptor agonist that produced the largest mean weight loss of any FDA-approved anti-obesity medication and beat semaglutide head-to-head.
  • Substantial weight reduction
  • Superior efficacy versus semaglutide
  • Glycemic control in type 2 diabetes
8 studiesdosing2 stacks
Noxa Labs — #1 research peptide supplier in the Philippines. Lab tested in CZ & USA, same-day Manila shipping. Save 15% with code LEARNPEPTIDE.